LeonaBio, Inc.
LONANasdaq
$7.22
↓ -7.6%Jul 17 close · end-of-day
Price
1Y↑ +88.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$137.4M
Enterprise Value
$69.7M
P/E
—
P/S
—
P/B
2.8
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$129.8M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-263.3%
ROIC
—
Debt / Equity
—
Net Cash
$67.7M
Return 1Y
+83.7%
Company profile
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in Phase 3 and ACT-AD clinical trials for the treatment of Alzheimer's disease.
- CEO
- Mark J. Litton
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- Washington
- Website
- athira.com
Management & directors
- Church KevinCHIEF SCIENTIFIC OFFICER
- Litton Mark JamesPRESIDENT and CEO
- Renninger RobertSVP, Finance and Accounting
- San Martin JavierCHIEF MEDICAL OFFICER
- Worthington MarkGENERAL COUNSEL and CCO
Roles derived from SEC Form 4 filings.
Earnings
LONA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.73↓ -26.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$20.0M | -$64.0M | -$104.0M | -$125.5M | -$100.9M | -$102.3M |
| Net income | -$20.0M | -$54.9M | -$95.6M | -$117.7M | -$97.0M | -$106.0M |
| Diluted EPS | — | -$1.49 | -$2.53 | -$3.09 | -$25.19 | -$24.70 |
| Operating cash flow | -$24.1M | -$43.1M | -$72.5M | -$100.8M | -$97.2M | -$45.7M |
| Free cash flow | -$26.4M | -$44.7M | -$73.6M | -$101.1M | -$97.2M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$28.0M | -$29.6M | -$15.6M | -$9.5M | -$7.3M | -$6.9M | -$78.6M | -$17.2M |
| Net income | -$26.9M | -$28.7M | -$15.1M | -$9.1M | -$7.0M | -$6.6M | -$83.3M | -$32.9M |
| Diluted EPS | -$0.70 | -$7.46 | -$16.34 | -$2.34 | -$0.18 | -$1.68 | -$20.50 | -$1.73 |
| Operating cash flow | -$22.3M | -$23.0M | -$26.0M | -$14.7M | -$7.0M | -$4.7M | -$19.4M | -$20.9M |
| Free cash flow | -$22.4M | -$23.0M | -$26.0M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 4, 2026
May 27, 2026
May 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-04 | Litton Mark James· PRESIDENT and CEO | Sale | 5,156 | $5.37 | $27,687.72 | filing |
| 2026-03-04 | San Martin Javier· CHIEF MEDICAL OFFICER | Sale | 1,720 | $5.37 | $9,236.40 | filing |
| 2026-03-04 | CHURCH KEVIN· CHIEF SCIENTIFIC OFFICER | Sale | 1,359 | $5.37 | $7,297.83 | filing |
| 2026-03-04 | Worthington Mark· GENERAL COUNSEL and CCO | Sale | 1,328 | $5.37 | $7,131.36 | filing |
| 2026-03-04 | Renninger Robert· CHIEF FINANCIAL OFFICER | Sale | 906 | $5.37 | $4,865.22 | filing |
| 2026-03-03 | Renninger Robert· CHIEF FINANCIAL OFFICER | Option exercise | 3,900 | $0.00 | $0.00 | filing |
| 2026-03-03 | Litton Mark James· PRESIDENT and CEO | Option exercise | 22,254 | $0.00 | $0.00 | filing |
| 2026-03-03 | Worthington Mark· GENERAL COUNSEL and CCO | Option exercise | 5,726 | $0.00 | $0.00 | filing |
| 2026-03-03 | CHURCH KEVIN· CHIEF SCIENTIFIC OFFICER | Option exercise | 5,856 | $0.00 | $0.00 | filing |
| 2026-03-03 | San Martin Javier· CHIEF MEDICAL OFFICER | Option exercise | 7,418 | $0.00 | $0.00 | filing |
| 2026-01-02 | Litton Mark James· President and CEO | Sale | 2,586 | $6.88 | $17,791.68 | filing |
| 2026-01-02 | San Martin Javier· CHIEF MEDICAL OFFICER | Sale | 1,644 | $6.88 | $11,310.72 | filing |
| 2026-01-02 | Worthington Mark· General Counsel and CCO | Sale | 876 | $6.88 | $6,026.88 | filing |
| 2026-01-02 | CHURCH KEVIN· CHIEF SCIENTIFIC OFFICER | Sale | 876 | $6.88 | $6,026.88 | filing |
| 2026-01-02 | Renninger Robert· Chief Financial Officer | Sale | 297 | $6.88 | $2,043.36 | filing |
| 2025-12-31 | San Martin Javier· CHIEF MEDICAL OFFICER | Option exercise | 4,667 | $0.00 | $0.00 | filing |
| 2025-12-31 | Litton Mark James· President and CEO | Option exercise | 10,834 | $0.00 | $0.00 | filing |
| 2025-12-31 | Renninger Robert· Chief Financial Officer | Option exercise | 1,236 | $0.00 | $0.00 | filing |
| 2025-12-31 | CHURCH KEVIN· CHIEF SCIENTIFIC OFFICER | Option exercise | 3,667 | $0.00 | $0.00 | filing |
| 2025-12-31 | Worthington Mark· General Counsel and CCO | Option exercise | 3,667 | $0.00 | $0.00 | filing |
| 2025-12-23 | PERCEPTIVE ADVISORS LLC | Award | 989,270 | $6.35 | $6.3M | filing |
| 2025-12-23 | PERCEPTIVE ADVISORS LLC | Award | 329,756 | $6.35 | $2.1M | filing |
| 2025-11-18 | Renninger Robert· Chief Financial Officer | Award | 1,000 | $2.31 | $2,310.00 | filing |
| 2025-11-18 | CHURCH KEVIN· CHIEF SCIENTIFIC OFFICER | Award | 1,000 | $2.31 | $2,310.00 | filing |
| 2025-07-01 | Litton Mark James· President and CEO | Sale | 25,123 | $0.29 | $7,373.60 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.